Intuitive Surgical, Inc. posted strong Q3 financial results, yet its stock dropped 6% due to market concerns over a $450 million settlement and a narrowed revenue guidance. The company is reducing prices on high-volume benign procedures to grow its market share, focusing on long-term adoption rather than immediate revenue per procedure. Despite slower U.S. procedure growth and a high price-to-earnings ratio projected for 2027, Intuitive Surgical's installed base and recurring revenue remain strong. The analyst maintains a premium valuation, believing market expectations underestimate the company's innovation and international expansion potential.
Intuitive Surgical trades at USD 431.42 on Pluang as of Oct 21, 2026 22:42 WIB, down 1.50% for the day. The stock's market cap stands at $154.74 billion with a 52-week high of $592.85. Trading volume reached 3,140,006 shares, with equal buy and sell orders at 50% each.
Intuitive Surgical reported third-quarter adjusted earnings of $3 per share, surpassing estimates of $2.65 per share, with revenue rising 22% year-over-year to $3.05 billion, beating the $2.91 billion consensus. Despite the strong financial results, ...
Intuitive Surgical announced a 22% increase in revenue to $3.05 billion for Q3 2026, driven by a 15% rise in worldwide procedures and increased system placements. The company settled an antitrust class action with a $450 million charge, impacting GAA...
